Navigation path

Otsingu tulemused

Otsingukriteeriumidele vastavate dokumentide arv: 38939
(Lehekülg 1 / 3894)

Dokumendi viitenumberVastutav peadirektoraatAvaldamise kuupäev
C(2018)9039/- SANTE (tervise ja toiduohutuse peadirektoraat) 14/12/2018
Komisjoni rakendusotsus
COMMISSION IMPLEMENTING DECISION concerning the transfer of the designation of "CD33-directed antibody-drug conjugate consisting of an antibody conjugated to a DNA cross-linking pyrrolobenzodiazepine dimer drug" as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council
C(2018)9038/- SANTE (tervise ja toiduohutuse peadirektoraat) 14/12/2018
Komisjoni rakendusotsus
COMMISSION IMPLEMENTING DECISION relating to the designation of "6,8-bis(benzylthio)octanoic acid" as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council
C(2018)9037/- SANTE (tervise ja toiduohutuse peadirektoraat) 14/12/2018
Komisjoni rakendusotsus
COMMISSION IMPLEMENTING DECISION relating to the designation of "Venglustat" as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council
C(2018)9036/- SANTE (tervise ja toiduohutuse peadirektoraat) 14/12/2018
Komisjoni rakendusotsus
COMMISSION IMPLEMENTING DECISION relating to the designation of "Sodium 2-hydroxylinoleate" as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council
C(2018)9035/- SANTE (tervise ja toiduohutuse peadirektoraat) 14/12/2018
Komisjoni rakendusotsus
COMMISSION IMPLEMENTING DECISION relating to the designation of "Pevonedistat" as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council
C(2018)9034/- SANTE (tervise ja toiduohutuse peadirektoraat) 14/12/2018
Komisjoni rakendusotsus
COMMISSION IMPLEMENTING DECISION relating to the designation of "Marizomib" as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council
C(2018)9033/- SANTE (tervise ja toiduohutuse peadirektoraat) 14/12/2018
Komisjoni rakendusotsus
COMMISSION IMPLEMENTING DECISION relating to the designation of "Lonafarnib" as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council
C(2018)9032/- SANTE (tervise ja toiduohutuse peadirektoraat) 14/12/2018
Komisjoni rakendusotsus
COMMISSION IMPLEMENTING DECISION relating to the designation of "Ivacaftor, potassium(benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl) cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide, tezacaftor" as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council
C(2018)9031/- SANTE (tervise ja toiduohutuse peadirektoraat) 14/12/2018
Komisjoni rakendusotsus
COMMISSION IMPLEMENTING DECISION relating to the designation of "Ivacaftor, N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, tezacaftor" as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council
C(2018)9030/- SANTE (tervise ja toiduohutuse peadirektoraat) 14/12/2018
Komisjoni rakendusotsus
DURCHFÜHRUNGSBESCHLUSS DER KOMMISSION über die Ausweisung des Arzneimittels "Humaner monoklonaler anti-Promyostatin-Antikörper" als Arzneimittel für seltene Leiden gemäß Verordnung (EG) Nr. 141/2000 des Europäischen Parlaments und des Rates

Otsingukriteeriumidele vastavate dokumentide arv: 38939
(Lehekülg 1 / 3894)